Cognitive manifestations of Huntington disease in relation to genetic structure and clinical onset

G. W. Jason, O. Suchowersky, E. M. Pajurkova, L. Graham, M. L. Klimek, A. T. Garber and D. Poirier-Heine
Department of Psychology, Foothills Hospital, Calgary, Alberta.

OBJECTIVE: To examine the cognitive manifestations of Huntington disease (HD) with respect to age, clinical onset, progression, and genetic analyses. DESIGN: Case series of people with HD or at risk (AR) for HD. SETTING: Movement disorders and medical genetics clinics. PARTICIPANTS: Volunteer sample of 50 patients with HD and 127 AR adults. MEASURES: Neuropsychological evaluation was conducted with multiple measures of cognitive function (intelligence, memory, attention, executive, spatial, language), strength, manual speed/dexterity, somatosensory function, and mood. Quantitative molecular genetic analysis by means of polymerase chain reaction was conducted on 31 patients with HD and 86 AR subjects. RESULTS: In clinical HD, cognitive impairment correlated with number of years affected but not age at onset. The linear regression had a negative intercept, suggesting impaired cognitive function by the time of onset. In AR gene carriers, lower cognitive performance correlated with more trinucleotide repeats. In clinical HD, trinucleotide repeats interacted with disease chronicity such that more repeats were associated with worse performance over time; the overall effect of this was small compared with the effect of disease chronicity alone. Except for one AR subject, mood state was not associated with cognitive performance in either patients with HD or AR subjects. CONCLUSIONS: Cognitive decline appears to start before clinical onset of HD and is correlated with the number of trinucleotide repeats. Subsequent cognitive decline is primarily a function of number of years affected, although there is evidence that the presence of more trinucleotide repeats is associated with faster deterioration.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The association of CAG repeat length with clinical progression in Huntington disease
Rosenblatt et al.
Neurology 2006;66:1016-1020.
ABSTRACT | FULL TEXT  

Huntington's disease: Clinical correlates of disability and progression
Mahant et al.
Neurology 2003;61:1085-1092.
ABSTRACT | FULL TEXT  

Cognitive and Motor Functioning in Gene Carriers for Huntington's Disease: A Baseline Study
Witjes-Ane et al.
J. Neuropsychiatry Clin. Neurosi. 2003;15:7-16.
ABSTRACT | FULL TEXT  

PACSIN 1 interacts with huntingtin and is absent from synaptic varicosities in presymptomatic Huntington's disease brains
Modregger et al.
Hum Mol Genet 2002;11:2547-2558.
ABSTRACT | FULL TEXT  

Evidence for Genetic Mediation of Executive Control: A Study of Aging Male Twins
Swan and Carmelli
J. Gerontol. B Psychol. Sci. Soc. Sci. 2002;57:P133-143.
ABSTRACT | FULL TEXT  

Clinical markers of early disease in persons near onset of Huntington's disease
Paulsen et al.
Neurology 2001;57:658-662.
ABSTRACT | FULL TEXT  

The genetic basis of cognition
Flint
Brain 1999;122:2015-2032.
ABSTRACT | FULL TEXT  

Neuropsychological abnormalities in first degree relatives of patients with familial Parkinson's disease
Dujardin et al.
J. Neurol. Neurosurg. Psychiatry 1999;67:323-328.
ABSTRACT | FULL TEXT  

Genetic Structure and Cognitive Function in Huntington Disease
JWatch Psychiatry 1998;1998:13-13.
FULL TEXT